ACON vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACON's deterministic health scores are severely compromised: the Piotroski F-Score of 1/9 signals extreme financial distress, and the absence of an Altman Z-Score (with negative profitability and liquidity anomalies) raises serious bankruptcy concerns. Despite a 31.5% YoY revenue growth, the company exhibits catastrophic profitability—negative gross, operating, and ROE margins—indicating fundamental operational failure. The stock trades at a price/sales of 52.03, vastly exceeding peers and suggesting extreme overvaluation relative to earnings. Analysts' target price of $23.00 is not supported by fundamentals, and insider activity remains neutral with no recent trades. The 5-year price decline of 100% underscores deep investor skepticism.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ACON vs LLY: Head-to-Head Comparison
This page compares Aclarion, Inc. (ACON) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.